Salivary caffeine in Parkinson's disease
Leodori G, De Bartolo MI, Belvisi D, Ciogli A, Fabbrini A, Costanzo M, Manetto S, Conte A, Villani C, Fabbrini G, Berardelli A
Scientific reports · 16 citas
Cómo se estudió
- Diseño
- Estudio de casos y controles (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2021-05-10 · Sci Rep · vol. 11 · número 1 · pág. 9823
- Editorial
- Nature Portfolio
- Citado
- 22 citas · más que el 87% de estudios similares · 1.8× el promedio de su campo
- Referencias
- 37 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Parkinson's Disease Mechanisms and Treatments · Coffee research and impacts · Neurological disorders and treatments
- Palabras clave
- Caffeine, Paraxanthine, Saliva, Parkinson's disease, Internal medicine, Medicine, Theophylline, Endocrinology, Physiology, Metabolism, Disease, CYP1A2
- MeSH
- saliva, humans, parkinson disease, caffeine, severity of illness index, case-control studies, aged, middle aged, female, male, healthy volunteers, biomarkers, mental status and dementia tests
11 autores
- Giorgio Leodori🇮🇹Istituto Neurologico Mediterraneo; Sapienza University of Rome
- Maria Ilenia De Bartolo🇮🇹Istituto Neurologico Mediterraneo
- Daniele Belvisi🇮🇹Istituto Neurologico Mediterraneo; Sapienza University of Rome
- Alessia Ciogli🇮🇹Sapienza University of Rome
- Andrea Fabbrini🇮🇹Sapienza University of Rome
- Matteo Costanzo🇮🇹Sapienza University of Rome
- Simone Manetto🇮🇹Sapienza University of Rome
- Antonella Conte🇮🇹Istituto Neurologico Mediterraneo; Sapienza University of Rome
- Claudio Villani🇮🇹Sapienza University of Rome
- Giovanni Fabbrini🇮🇹Istituto Neurologico Mediterraneo; Sapienza University of Rome
- Alfredo Berardelli🇮🇹 · autor de correspondenciaIstituto Neurologico Mediterraneo; Sapienza University of Rome
Resumen
El texto original del estudio, en el idioma en que se publicó.
We aimed to investigate salivary caffeine content, caffeine absorption and metabolism in Parkinson's disease (PD) and verify whether salivary caffeine can be used as a biomarker of PD. We enrolled 98 PD patients and 92 healthy subjects. Caffeine and its major metabolite, paraxanthine, were measured in saliva samples collected before and 4 h after the oral intake of caffeine (100 mg). We measured caffeine absorption as the normalized increase in caffeine levels, and caffeine metabolism as the paraxanthine/caffeine ratio. The Movement Disorder Society Unified Parkinson's Disease Rating Scale part III, the Hoehn & Yahr, the presence of motor complications, and levodopa equivalent dose (LED) were assessed and correlated with caffeine levels, absorption, and metabolism. The effects of demographic and environmental features possibly influencing caffeine levels were also investigated. Caffeine levels were decreased in patients with moderate/advanced PD, while caffeine levels were normal in patients with early and de-novo PD, unrelated to caffeine intake. Caffeine absorption and metabolism were normal in PD. Decreased salivary caffeine levels in PD were associated with higher disease severity, longer duration, and the presence of motor complications, no significant association was found with LED. Salivary caffeine decrease correlates with PD progression.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.